Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

Cancer immunotherapy is undergoing significant progress due to recent clinical successes by refined adoptive T-cell transfer and immunostimulatory monoclonal Ab (mAbs). B16F10-derived OVA-expressing mouse melanomas resist curative immunotherapy with either adoptive transfer of activated anti-OVA OT1...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Proc Natl Acad Sci U S A
Egile Nagusiak: Weigelin, Bettina, Bolaños, Elixabet, Teijeira, Alvaro, Martinez-Forero, Ivan, Labiano, Sara, Azpilikueta, Arantza, Morales-Kastresana, Aizea, Quetglas, José I., Wagena, Esther, Sánchez-Paulete, Alfonso Rodríguez, Chen, Lieping, Friedl, Peter, Melero, Ignacio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: National Academy of Sciences 2015
Gaiak:
Biological Sciences
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4475992/
https://ncbi.nlm.nih.gov/pubmed/26034288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1506357112
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak